AdagrasibasibpembrolizumabsotorasibBI-2493G12CidocetaxeldaraxonrasibAZD4785RMC-7977
…d OS of 13.4 months,38 39 leading to full FDA approval in 2024. Adagrasib has also shown modest activity in PDAC (ORR 33%, PFS 5.4 months…
3articles mentioning drugs
8drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: panitumumab ×
panitumumab
This drug is selected. Its supporting articles are shown below.
Articles mentioning panitumumab
3 articles · page 1 of 1pembrolizumabbortezomibcrizotinibpembrolizumab35sunitinibdasatinib
…umab) are often used in ovarian and cervical cancers. ICIs (eg, pembrolizumab) are effective in mismatch repair-deficient endometrial cancer …
bevacizumabcarboplatin5-fluorouracilgemcitabinecisplatinnivolumabpemetrexedpembrolizumabirinotecanoxaliplatin+8 more
…ounded 60 bags of 19 different drugs, including 5-fluorouracil, bevacizumab, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubic…